[
    {
        "molecule_name": "(−)-vesamicol",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "4.4±0.6",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "6.7±0.4",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-vesamicol",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "73.8±11.2",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-vesamicol",
        "protein_target_name": "δ-2 receptor",
        "binding_metric": "Ki",
        "value": "346±37",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "33.7±5.9",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "δ-2 receptor",
        "binding_metric": "Ki",
        "value": "266±28",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "σ-1",
        "binding_metric": "IC50",
        "value": "16",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "VAChT",
        "binding_metric": "IC50",
        "value": "38",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "σ-2 Receptor",
        "binding_metric": "IC50",
        "value": "32",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-Vesamicol",
        "protein_target_name": "σ-1",
        "binding_metric": "IC50",
        "value": "13",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-Vesamicol",
        "protein_target_name": "VAChT",
        "binding_metric": "IC50",
        "value": "13",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-Vesamicol",
        "protein_target_name": "σ-2 Receptor",
        "binding_metric": "IC50",
        "value": "0",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-Vesamicol",
        "protein_target_name": "Receptor#",
        "binding_metric": "IC50",
        "value": "4",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "SA4503",
        "protein_target_name": "σ-1",
        "binding_metric": "IC50",
        "value": "12",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "SA4503",
        "protein_target_name": "VAChT",
        "binding_metric": "IC50",
        "value": "05",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "SA4503",
        "protein_target_name": "σ-2 Receptor",
        "binding_metric": "IC50",
        "value": "1.28",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "Haloperidol",
        "protein_target_name": "σ-1",
        "binding_metric": "IC50",
        "value": "9",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "Haloperidol",
        "protein_target_name": "VAChT",
        "binding_metric": "IC50",
        "value": "73.0",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "Haloperidol",
        "protein_target_name": "σ-2 Receptor",
        "binding_metric": "IC50",
        "value": "1",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "Haloperidol",
        "protein_target_name": "Receptor#",
        "binding_metric": "IC50",
        "value": "90",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(+)-Pentazocine",
        "protein_target_name": "σ-1",
        "binding_metric": "IC50",
        "value": "8",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(+)-Pentazocine",
        "protein_target_name": "VAChT",
        "binding_metric": "IC50",
        "value": "3",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(+)-Pentazocine",
        "protein_target_name": "σ-2 Receptor",
        "binding_metric": "IC50",
        "value": "0",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(+)-Pentazocine",
        "protein_target_name": "Receptor#",
        "binding_metric": "IC50",
        "value": "6.3",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "6.7 ± 0.4",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "33.7 ± 5.9",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "δ-2 receptor",
        "binding_metric": "Ki",
        "value": "266 ± 28",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-vesamicol",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "4.4 ± 0.6",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-vesamicol",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "73.8 ± 11.2",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-vesamicol",
        "protein_target_name": "δ-2 receptor",
        "binding_metric": "Ki",
        "value": "346 ± 37",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "SA4503",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "50.2 ± 7.2",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "SA4503",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "4.4 ± 1.0",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "SA4503",
        "protein_target_name": "δ-2 receptor",
        "binding_metric": "Ki",
        "value": "242 ± 17",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "haloperidol",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "41.4 ± 17.6",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "haloperidol",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "2.6 ± 0.8",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "haloperidol",
        "protein_target_name": "δ-2 receptor",
        "binding_metric": "Ki",
        "value": "167 ± 19",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(+)-pentazocine",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "315 ± 12",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(+)-pentazocine",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "15.5 ± 2.0",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-iodovesamicol",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "15.0±2.9",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-iodovesamicol",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "62.2±12.0",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-iodovesamicol",
        "protein_target_name": "δ-2 receptor",
        "binding_metric": "Ki",
        "value": "554±137",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "VAChT",
        "binding_metric": "Ki",
        "value": "6.7±0.4",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "δ-1 receptor",
        "binding_metric": "Ki",
        "value": "33.7±5.9",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    },
    {
        "molecule_name": "(−)-o-MeVES",
        "protein_target_name": "δ-2 receptor",
        "binding_metric": "Ki",
        "value": "266±28",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n1. The Ki value indicating the affinity of (−)-vesamicol for VAChT is 4.4±0.6 nM, and the Ki value indicating the affinity of the (−)-o-MeVES of the present invention for VAChT is 6.7±0.4 nM.\n2. Also, the Ki values of the affinity of (−)-vesamicol for the δ-1 receptor and δ-2 receptor are 73.8±11.2 nM and 346±37 nM, respectively, and the Ki values indicating the affinity of the (−)-o-MeVES of the present invention for the δ-1 receptor and δ-2 receptor are 33.7±5.9 nM and 266±28 nM, respectively.\n3. TABLE 1-1 IC50 (nM) σ-1 VAChT* Receptor# σ-2 Receptor$ (−)-o-MeVES 16 38 32 0 (−)-Vesamicol 13 13 0 4 20 SA4503 12 05 1.28 0 Haloperidol 9 73.0 1 90 (+)-Pentazocine 8 3 0 6.3 —\n4. TABLE 1-2 Ki(nM) VAChT δ-1 receptor δ-2 receptor (−)-o-MeVES 6.7 ± 0.4 33.7 ± 5.9  266 ± 28 (−)-vesamicol 4.4 ± 0.6 73.8 ± 11.2  346 ± 37 SA4503 50.2 ± 7.2  4.4 ± 1.0  242 ± 17 haloperidol 41.4 ± 17.6  2.6 ± 0.8  167 ± 19 (+)-pentazocine 315 ± 12 15.5 ± 2.0  —\n5. As a result of in vitro experiments using the rat brain, the affinity of (−)-o-iodovesamicol for VAChT, δ-1 receptor, and δ-2 receptor were 15.0±2.9 nM, 62.2±12.0 nM, and 554±137 nM, respectively, as Ki values (mean±standard deviation).\n6. From Table 1-2, the Ki values of the (−)-o-MeVES of the present invention for VAChT, δ-1 receptor, and δ-2 receptor were 6.7±0.4 nM, 33.7±5.9 nM, and 266±28 nM, respectively."
    }
]